Base Pair Biotechnologies
Base Pair Biotechnologies specializes in custom aptamer discovery and development for research, diagnostics, therapeutics, and industrial applications. The company leverages proprietary multiplex selection, advanced bioinformatics, and chemical modification techniques to develop high-affinity and selective nucleic acid aptamers. Base Pair enables affinity reagent development, biosensor design, and molecular detection for a broad range of targets and partners across academia and industry.
Base Pair Biotechnologies
8619 Broadway Street, Suite 100, Pearland, TX 77584 USA
Patents
Methods and materials for discovery of functional ligands to molecular complexes
2025-06-24 • US-12338434-B1
View DetailsMethods and materials for multiplexed collections of functional ligands
2024-04-30 • US-11970785-B2
View Details
Methods and materials for discovery of functional ligands to molecular complexes
2025-06-24 • US-12338434-B1
View DetailsMethods and materials for multiplexed collections of functional ligands
2024-04-30 • US-11970785-B2
View DetailsWhat We Do
Chemically synthesized oligonucleotide aptamers specific for a broad range of validated targets, available for research and diagnostic use.
DNA aptamers identified and validated to inhibit the oxidation of vitamin C, offering stabilization for use in food, beverages, and nutraceutical formulations.
Consultative and collaborative discovery of single- or multiplex aptamers tailored to user-defined targets through iterative SELEX and optimization.
Development and optimization of aptamer-based assays for diagnostics, detection, and biosensor applications, including lateral flow, ELASA, and other plate-based formats.
Analysis of aptamer selection data using next-generation sequencing and clustering and alignment algorithms to identify high-affinity candidates.
Enhancement of aptamer function via truncation, base substitution, and conjugation with chemical groups for improved stability, solubility, detection, or target affinity.
Chemically synthesized oligonucleotide aptamers specific for a broad range of validated targets, available for research and diagnostic use.
DNA aptamers identified and validated to inhibit the oxidation of vitamin C, offering stabilization for use in food, beverages, and nutraceutical formulations.
Consultative and collaborative discovery of single- or multiplex aptamers tailored to user-defined targets through iterative SELEX and optimization.
Development and optimization of aptamer-based assays for diagnostics, detection, and biosensor applications, including lateral flow, ELASA, and other plate-based formats.
Analysis of aptamer selection data using next-generation sequencing and clustering and alignment algorithms to identify high-affinity candidates.
Enhancement of aptamer function via truncation, base substitution, and conjugation with chemical groups for improved stability, solubility, detection, or target affinity.
Application Area
Infectious Diseases
Regenerative Medicine
Biologics
Vaccines
Diagnostics
Digital Health Technologies
Drugs
Services
Key People
Founder and Chief Scientist
General Counsel
Founder and Chief Scientist
General Counsel
News & Updates
Awarded a CDC grant for development of aptamers and lateral flow assays for rapid detection of synthetic opioids on surfaces.
Awarded a grant from the CDC to develop aptamer-based point-of-care tests for detection of malarial metabolites in urine and saliva.
Awarded an SBIR grant to develop aptamer-based point-of-care tests for opioids to rapidly diagnose neonatal abstinence syndrome.
Awarded a NIH SBIR contract for development and validation of non-mouse reagents for preclinical development of novel therapeutics, focusing on canine models for oncology research.
Discovery of aptamers capable of inhibiting vitamin C oxidation, with implications for food, beverages, supplements, and cosmetics.
Coverage of aptamers as alternatives to immunization and patented custom aptamer development.
Awarded a CDC grant for development of aptamers and lateral flow assays for rapid detection of synthetic opioids on surfaces.
Awarded a grant from the CDC to develop aptamer-based point-of-care tests for detection of malarial metabolites in urine and saliva.
Awarded an SBIR grant to develop aptamer-based point-of-care tests for opioids to rapidly diagnose neonatal abstinence syndrome.
Awarded a NIH SBIR contract for development and validation of non-mouse reagents for preclinical development of novel therapeutics, focusing on canine models for oncology research.
Discovery of aptamers capable of inhibiting vitamin C oxidation, with implications for food, beverages, supplements, and cosmetics.
Coverage of aptamers as alternatives to immunization and patented custom aptamer development.